spacer
home > epc > autumn 2008 > be alternative
PUBLICATIONS
European Pharmaceutical Contractor

Be Alternative

In preclinical drug development, in vitro studies are establishing themselves in a more prominent position. Because of ethical considerations, an increasing number of in vivo tests have been replaced by in vitro experiments. These tests are recommended by organisations such as the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM), and (draft) Test Guidelines are accepted or sent for consideration to the European Medicines Agency (EMEA), the US Food and Drug Administration (FDA) and the Organization of Economic Cooperation and Development (OECD), which are all part of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human use (ICH).

The National Institutes of Health (NIH) and other federal agencies are committed to the welfare of research animals. These animals are protected by law, regulations and policies to ensure that companies are sued as rarely as possible and with special care taken in order to ensure animals’ comfort. Alternative test methods are those that accomplish one or more of the three ‘Rs’:

  • Reducing the number of animals used in testing through improved science and experimental design
  • Refining experimental procedures so that animals experience less pain and distress
  • Replacing animals with non-animal systems where possible

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Natalie MGM Appels obtained her Masters degree in Biopharmaceutical Sciences from the University of Leiden in 1998. Her career as a research scientist began at the spin-off company ScreenTec BV currently known as Kiadis BV. She received her PhD from the Netherlands Cancer Institute. Since 2006, she has been employed by NOTOX BV as a Study Director in the In Vitro ADME section.

Ilona Verbaan-Giebelen obtained her Masters degree in Medical Biology from the Free University of Amsterdam in 1999. She has worked as a Research Technician at Organon NV and received her PhD from the Centre for Experimental and Molecular Medicine at the Academic Medical Centre in Amsterdam. She joined NOTOX BV in 2008 as Study Director, Genetic and In Vitro Toxicology.

spacer
Natalie MGM Appels
spacer
spacer
spacer
Ilona Verbaan-Giebelen
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Signant Health Appoints Lawrence Miller as Chief Technology Officer

LONDON & PHILADELPHIA – June 13, 2019: Signant Health, formerly CRF Bracket, has appointed Lawrence Miller as Chief Technology Officer. Signant unites electronic Clinical Outcomes Assessment (eCOA), eConsent, Patient Engagement, Interactive Response Technology (IRT), Clinical Supply Management and Endpoint Quality into the industry’s most comprehensive patient-centric suite of technology solutions and services. An accomplished innovator, Miller brings unique vision and expertise to a Signant team already committed to advancing clinical research with its next-generation technology portfolio.
More info >>

White Papers

Preparation of Pharmaceutical Samples for Metals Analysis

RSSL

There has been a lot of discussion regarding the methods of analysis for pharmaceutical products as we await the upcoming changes to both the EP and USP, relating to the analysis of metal impurities.
More info >>

 
Industry Events

CPhI & P-MEC India

26-28 November 2019, India Expo Centre, Greater Noida, Delhi NCR, India

As the pharma industry looks increasingly towards India for high quality, low cost pharma solutions, CPhI & P-MEC India is the ideal event for companies wanting to pick up on the latest trends and innovations the market has to offer. At CPhI & P-MEC India, you will meet the movers and shakers from India's pharma machinery, technology and ingredients industries, giving you a competitive advantage that will help grow your business.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement